Cardiac diseases such as myocardial infarction and heart failure are among the leading causes of death in western societies. Therapeutic angiogenesis has been suggested as a concept to combat these diseases. The biology of angiogenic factors expressed in the heart such as vascular endothelial growth factor (VEGF) is well studied, whereas data on anti-angiogenic mediators in the heart are scarce. Here we study the expression of the anti-angiogenic factor pigment epithelium-derived factor (PEDF) 
Introduction
Cardiac diseases such as myocardial infarction and heart failure are among the leading causes of death in western societies. One attractive and promising approach to combat excessive damage of the heart muscle after injury is to therapeutically modulate angiogenesis, the growth of new blood vessels. Accumulating evidence suggests a role for the heart as a source of growth factors and cytokines involved in the regulation of angiogenesis [1] . The biology of angiogenic factors expressed in the heart such as vascular endothelial growth factor (VEGF), various fibroblast growth factors (FGFs), hepatocyte growth factor (HGF) or angiopoietin-1 (Ang-1) has been extensively investigated. In contrast, studies on a possible involvement of anti-angiogenic mediators in the pathophysiology of cardiovascular disease are scarce [2] .
Here we studied a possible role of the anti-angiogenic protein pigment epithelium-derived factor (PEDF) in the human heart. PEDF, a 50-kD non-inhibitory member of the serpin family, is widely expressed in various tissues throughout the body such as the skeletal muscle, adipose tissues, liver and bone and is also found in the plasma [3] . [4, 5] 3, 8 and 9 [3] . In [7] . These findings suggest a possible protective role for PEDF in cardiovascular disease. In addition PEDF has been localized recently in atherosclerotic plaques [8] 
PEDF is a multifunctional protein with neurotrophic, neuroprotective, antioxidant, anti-inflammatory and also anti-angiogenic properties. It suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and proliferation of endothelial cells

. Recently it has been shown that PEDF induces apoptosis in endothelial cells by activating FAS-FAS ligand death pathway and p38 MAP kinase dependent cleavage of caspase
Material and methods
Preparation of human tissue
Isolation and cultivation of human cells
Human adult cardiac myocytes (HACM), human adult cardiac fibroblasts (HACF) and human umbilical vein endothelial cells (HUVEC)
were isolated, cultivated and characterized as previously described [9, 10] . 
Spheroid sprouting assay
The in vitro angiogenesis assay using collagen gel-embedded HUVEC spheroids was performed as described by Korff et al. [11] . Fig. 1A and B) . The highest levels of PEDF protein were found in healthy hearts whereas these levels were reduced in heart tissue from patients suffering from ischemic or dilatative cardiomyopathy (Fig. 1A) (Fig. 1A) . mRNA levels for PEDF in ischemic hearts were lower as compared to mRNA levels in healthy hearts and in dilated hearts (Fig. 1B) 
The collagen gelembedded spheroids were stimulated with 50 ng/ml rh VEGF (R&D Systems), 500 ng/ml rh PEDF or both for 24 hrs. Spheroid sprouting was analysed measuring the total area of spheroids and mean distance of sprouts from the focal point (S.CO LifeScience GmbH, Garching, Germany).
Statistical analysis
Experiments were repeated at least three times, one representative experiment is shown. Data were compared statistically by t-test (independent variables). Values of P Ͻ 0.05 were considered significant.
Results and discussion
We present here evidence that the potent anti-angiogenic protein PEDF is expressed in human hearts. As revealed by Western blotting and PCR, we show that PEDF protein and mRNA is present in the human heart (
Fig. 3 PEDF inhibits VEGF-induced sprouting. Spheroids were cultivated in the absence (control) or presence of PEDF, VEGF or both PEDF and VEGF for 24 hrs (A). Sprouting was analysed measuring the total area (pixel) of the spheroids (n ϭ 8) (B) and the mean distance (pixel) of the sprouts from the focal point (C). Values represent mean values
to healthy hearts. These mRNA levels were also reduced in patients suffering from dilatative cardiomyopathy. However, this latter decrease did not reach significance (Fig. 1D) [5, 13] . Due to low oxygen concentration the HIF is stabilized and transported to the nucleus [14] . To Fig. 2A and B) . These data were confirmed at mRNA level (Fig. 2C) . Furthermore we showed an increased accumulation of HIF-1␣ in the nuclear extract of cardiac myocytes and fibroblasts stimulated with CoCl2, DP and DMOG or cultivated under anoxic conditions (Fig. 2D) . In addition we detected increased HIF-1␣ expression in the lysate of these cells (data not shown). There is convincing evidence that the expression of the proangiogenic factor VEGF is strongly increased by ischemia [14] . In agreement with published data we detected increased VEGF levels in human cardiac cells cultivated under anoxic conditions (Table 1) , resulting in an increased VEGF/PEDF ratio [14] . The reciprocal regulation of PEDF and VEGF by anoxia has also been reported in the retina and in retinal cells [5, 13] To evaluate the anti-angiogenic effect of PEDF [4, 5] we performed a spheroid sprouting assay. PEDF inhibited VEGF-induced sprouting of spheroids (Fig. 3A) . The total area of spheroids stimulated with PEDF and VEGF and the mean distance of the sprouts from the focal point were significantly reduced compared to VEGF stimulated spheroids. PEDF alone did not show any effect (Fig. 3B  and C) . Our results are in line with the notion that PEDF directly affects VEGF-induced angiogenesis [19] . In contrast to angiogenic mediators such as VEGF and FGFs, whose presence and regulation in the heart have been extensively studied, information on anti-angiogenic factors in the heart is scarce [1] . Recently, expression of endostatin and angiostatin has been described in diabetic porcine myocardium [20] . Here we have identified yet another anti-angiogenic mediator, namely PEDF, in the heart. Given its regulated presence in the human heart and its potent anti-angiogenic effect, PEDF could be considered as a promising candidate for therapeutic modulation of angiogenesis. Using PEDF therapeutically to inhibit angiogenesis or induce vessel regression has already been suggested in diseases like cancer, retinopathy or arthritis [3] . On the other hand blocking PEDF efficiently in the heart -possibly in concert with simultaneous administration of angiogenic factors or stem cells -could result in increased revascularization, healing and regeneration of ischemic heart tissue with beneficial consequences for patients suffering from ischemic heart disease [21, 22] . However, as our study is limited to the expression and regulation of PEDF in the heart, further studies are warranted to more closely define its function and pathophysiological role in this organ.
